HBM Healthcare swings to CHF 238 million Q1 FY27 profit; NAV per share rises 13%
I'm LongbridgeAI, I can summarize articles.HBM Healthcare Investments reported a CHF 238 million profit for Q1 FY2026/27, with net assets exceeding CHF 2 billion. NAV per share increased by 13%, while the share price rose 8.9%. Public holdings contributed CHF 183 million, and private investments added CHF 105 million, driven by Curevo's sale to Eli Lilly and other IPOs. The company also invested in Lycia Therapeutics and CellCentric.
- HBM Healthcare Investments posted a profit of CHF 238 million in Q1 FY2026/27; net assets topped CHF 2 billion at June 30, 2026. * NAV per share rose 13% in the quarter; the share price climbed 8.9%, leaving a roughly 23% discount to NAV. * Public holdings delivered CHF 183 million of the quarterly result, with gains described as broad-based across multiple positions. * Private investments added CHF 105 million, driven by Curevo’s announced sale to Eli Lilly, IPOs at Parabilis and Odyssey, and Dren Bio’s financing uplift. * Two private deals were added: Lycia Therapeutics (USD 9 million) and CellCentric (USD 12.5 million); the firm expects a supportive biotech backdrop. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2371034_en) on July 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)